pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements